Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
Forsteo® (teriparatide): Pregnancy During Treatment
Forsteo is contraindicated for use in women who are pregnant. If pregnancy occurs, Forsteo should be discontinued.
Forsteo is contraindicated for use during pregnancy.1
Women of childbearing potential should use effective methods of contraception during use of Forsteo. If pregnancy occurs, Forsteo should be discontinued.1
Clinical Data in Humans
Data from Studies in Animals
Teriparatide was not genotoxic in a standard battery of tests. It produced no teratogenic effects in rats, mice or rabbits. There were no important effects observed in pregnant rats or mice administered teriparatide at daily doses of 30 to 1000 µg/kg. However, fetal resorption and reduced litter size occurred in pregnant rabbits administered daily doses of 3 to 100 µg/kg. The embryotoxicity observed in rabbits may be related to their much greater sensitivity to the effects of PTH on blood ionised calcium compared with rodents.1
1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: February 05, 2020